QUASAR试验中CD3和CD8 T细胞免疫组化对早期结直肠癌预后评估及辅助化疗获益预测的评价
在QUASAR试验868例II/III期结直肠癌患者中,用CD3和CD8免疫组化计算核心肿瘤与浸润边缘的T细胞密度,评估其预后价值及对辅助化疗获益的预测作用。高危组复发率约为低危组的两倍,但化疗的相对复发下降在高危和低危组相似,CD3评分可分层并得出不同NNT。
要点
- 高危CD3/CD8组复发率约为低危组的两倍
- 辅助化疗的相对复发下降在高危和低危组相似
- CD3评分分高、中、低危组,预防1例复发的NNT分别为11、21、36
核心结论
- 高危CD3/CD8组复发率约为低危组的两倍,化疗的相对下降相似,QUASAR得出的NNT可用当代非随机数据集更新。
研究设计与样本
- QUASAR试验中868例II/III期结直肠癌患者,随机接受辅助氟尿嘧啶/亚叶酸钙或观察,肿瘤组织行CD3和CD8免疫组化,由病理学家借助人工智能计算核心肿瘤和浸润边缘的细胞密度(细胞/mm2),参与者随机分为训练集和验证集,主要结局为无复发生存间期(RFI),以2年RFI评估生物标志物-治疗交互作用,用最大似然法在训练集确定高危/低危组最佳切点,并在验证集重复预后分析。
主要发现
- 训练集中,高危组复发率在所有指标上均为低危组的两倍:CD3-核心肿瘤的率比(RR)为2.00(P=0.0008),CD3-浸润边缘为2.38(P<0.00001),CD8-核心肿瘤为2.17(P=0.0001),CD8-浸润边缘为2.13(P=0.0001);验证集 closely 重复了这一结果,RR分别为1.96、1.79、1.72、1.72。
- 多变量分析中,预后效应在结肠癌与直肠癌、II期与III期疾病中相似。
- 辅助化疗带来的复发比例下降在高复发风险组和低复发风险组幅度相似。
- 联合CD3-浸润边缘和CD3-核心肿瘤信息(CD3评分)生成高、中、低危组,预防一例疾病复发所需治疗人数(NNT)分别为11、21和36。
关键数值与推荐
- CD3-核心肿瘤高危组与低危组复发率比RR为2.00(P=0.0008),验证集RR为1.96。
- CD3-浸润边缘高危组与低危组复发率比RR为2.38(P<0.00001),验证集RR为1.79。
- CD8-核心肿瘤高危组与低危组复发率比RR为2.17(P=0.0001),验证集RR为1.72。
- CD8-浸润边缘高危组与低危组复发率比RR为2.13(P=0.0001),验证集RR为1.72。
- CD3评分高、中、低危组预防一例复发的NNT分别为11、21和36。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: High densities of tumor infiltrating CD3 and CD8 T-cells are associated with superior prognosis in colorectal cancer (CRC). Their value as predictors of benefit from adjuvant chemotherapy is uncertain. PATIENTS AND METHODS: Tumor tissue from 868 patients in the QUASAR trial (adjuvant fluorouracil/folinic acid v observation in stage II/III CRC) was analyzed by CD3 and CD8 immunohistochemistry. Pathologists, assisted by artificial intelligence, calculated CD3 and CD8 cell densities (cells/mm2) in the core tumor (CT) and invasive margin (IM). Participants were randomly partitioned into training and validation sets. The primary outcome was recurrence-free interval (RFI), 2-year RFI for assessment of biomarker-treatment interactions. Maximum-likelihood methods identified optimal high-risk/low-risk group cutpoints in the training set. Prognostic analyses were repeated in the validation set. RESULTS: In the training set, the recurrence rate in the high-risk group was twice that in the low-risk group for all measures (CD3-CT: rate ratio [RR], 2.00, P = .0008; CD3-IM: 2.38, P < .00001; CD8-CT: 2.17, P = .0001; CD8-IM: 2.13, P = .0001). This was closely replicated in the validation set (RR, 1.96, 1.79, 1.72, 1.72, respectively). In multivariate analyses, prognostic effects were similar in colon and rectal cancers, and in stage II and III disease. Proportional reductions in recurrence with adjuvant chemotherapy were of similar magnitude in the high- and low-recurrence risk groups. Combining information from CD3-IM and CD3-CT (CD3 Score) generated high-, intermediate-, and low-risk groups with numbers needed to treat (NNTs) to prevent one disease recurrence being 11, 21, and 36, respectively. CONCLUSION: Recurrence rates in the high-risk CD3/CD8 groups are twice those in the low-risk groups. Proportional reductions with chemotherapy are similar, allowing NNTs derived in QUASAR to be updated using contemporary, nonrandomized data sets.
引用
- Williams CJM, Gray R, Hills RK, et al. Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial. J Clin Oncol. 2024. PMID: 39083705. doi:10.1200/JCO.23.02030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。